Harrow Reports Q1 Revenue of $44.2M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy HROW?
Reports Q1 revenue $44.2M vs. $47.83M last year. "The demand for Harrow's key products has never been stronger, and our visibility into our demand trajectory - across our portfolio - keeps us entirely on track to reach our forecasted financial goals for the year," said Mark L. Baum, Chief Executive Officer of Harrow. "Although our first-quarter reported revenue reflects an estimated $8 million gross-to-net reduction associated with our new commercial coverage for VEVYE, this adjustment does not reflect the profitable, recurring, and significant patient base established during the quarter. Harrow is now positioned to realize the full financial benefits of this coverage relationship beginning in Q2 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HROW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HROW
Wall Street analysts forecast HROW stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.230
Low
63.00
Averages
72.40
High
94.00
Current: 38.230
Low
63.00
Averages
72.40
High
94.00
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LogiCare3PL Selected as Distribution Partner for Harrow's Ophthalmic Solutions
- Partnership Formation: LogiCare3PL was officially selected as a distribution partner for Harrow, Inc. effective February 1, 2026, providing both non-title and 3PL title distribution services to support Harrow's product distribution across the U.S., thereby enhancing Harrow's market access capabilities.
- Rapid Implementation Capability: LogiCare3PL successfully onboarded Harrow within just four weeks, meeting Harrow's implementation timeline and ensuring business continuity, which significantly improves Harrow's responsiveness in the competitive ophthalmic disease management market.
- High-Touch Service Model: LogiCare3PL was chosen for its high-touch service model and proven ability to execute quickly and efficiently, which not only met Harrow's need for rapid market readiness but also laid the groundwork for a long-term partnership between the two companies.
- Future Collaboration Outlook: Both organizations anticipate continued collaboration as Harrow expands its product offerings, with LogiCare3PL providing a full suite of 3PL services to further enhance Harrow's competitive position in the ophthalmic sector.
See More
LogiCare3PL Partners with Harrow for Ophthalmic Solutions Distribution
- Partnership Formation: LogiCare3PL officially became a distribution partner for Harrow, Inc. on February 1, 2026, providing both non-title and 3PL title distribution services, significantly enhancing Harrow's market access speed and cost-effectiveness in the U.S. market.
- Rapid Implementation Capability: LogiCare3PL successfully onboarded Harrow within just four weeks, meeting Harrow's implementation timeline and ensuring business continuity, showcasing LogiCare3PL's excellence in efficient execution and customer support.
- High-Touch Service Model: LogiCare3PL was selected for its high-touch service model and customer-centric flexibility, which not only met Harrow's need for rapid market readiness but also strengthened the long-term partnership between the two organizations.
- Future Collaboration Outlook: Both parties anticipate continued collaboration as Harrow expands its product offerings, with LogiCare3PL providing a full suite of 3PL services to further drive Harrow's growth in the ophthalmic disease management solutions sector.
See More
Harrow Prices $50 Million Private Offering of Senior Unsecured Notes
- Bond Offering Size: Harrow announced a private offering of $50 million in senior unsecured notes with an interest rate of 8.625% per annum, maturing in 2030, which will strengthen the company's capital structure and provide funding for future growth.
- Clear Use of Proceeds: The net proceeds from this bond issuance will be allocated for general corporate purposes, including new product launches, development activities, and strategic business opportunities, indicating the company's proactive approach to future expansion.
- Connection to Previous Issuance: The new notes will be issued under the same indenture as the previously issued $250 million of 2030 notes in September 2025, enhancing investor confidence in Harrow's debt profile.
- Issuance Timeline: The offering is expected to close on March 27, 2026, reflecting the company's active engagement in the capital markets and its focus on future financial flexibility.
See More
Harrow Plans to Issue $50M in Senior Unsecured Notes
- Bond Issuance Plan: Harrow announced its intention to offer $50 million in 8.625% senior unsecured notes due 2030, which will form a single series with the $250 million notes issued in September 2025, sharing identical terms except for issuance date and price.
- Clear Use of Proceeds: The net proceeds from this bond issuance will be allocated for general corporate purposes, including growth initiatives, product development, and potential strategic investments, indicating the company's proactive approach to future development.
- Positive Market Reaction: Following the announcement, Harrow's shares rose by 2.16%, reflecting investor confidence in the company's financing strategy and its future growth potential.
- Revenue Target Set: Harrow has set a revenue goal of $350 million to $365 million for 2026, anticipating performance growth driven by sales force expansion and pipeline advancements, further solidifying its dominant position in the U.S. ophthalmic market.
See More
Opaleye Management Inc. Indirectly Sells Harrow Shares Worth $7.8 Million
- Transaction Overview: Opaleye Management Inc. reported the indirect sale of 198,572 shares of Harrow common stock on March 3 and 4, 2026, totaling approximately $7.8 million, demonstrating its strategic maneuvering in a volatile market.
- Post-Transaction Holdings: Following the sale, Opaleye L.P. retains 3,622,000 shares and the managed account holds 59,428 shares, resulting in a combined indirect position of about 3.68 million shares, indicating that it remains a significant shareholder with nearly 10% ownership in Harrow.
- Market Reaction Analysis: While the nearly $8 million stock sale might suggest a lack of confidence, the context reveals that it occurred after Harrow's Q4 2025 earnings report, where the stock dropped sharply, making the sale appear more like opportunistic profit-taking rather than a fundamental outlook change.
- Investor Perspective: The shares sold represent roughly 5% of Opaleye's total pre-sale position, suggesting that the fund still has a strong belief in Harrow's long-term prospects, with this adjustment likely being tactical rather than a strategic retreat, reflecting confidence in Harrow's future growth potential.
See More
Opaleye Management Sells 198,572 Shares of Harrow Stock
- Sale Overview: Opaleye Management Inc. indirectly sold 198,572 shares of Harrow stock on March 3 and 4, 2026, for approximately $7.8 million, based on weighted average prices of $39.15 and $39.67, indicating opportunistic profit-taking following the company's earnings report.
- Holding Analysis: Despite the sale suggesting a potential lack of confidence in Harrow, Opaleye retains about 3.68 million shares, representing nearly 10% of Harrow's total shares, highlighting its continued role as a significant institutional backer.
- Financial Performance and Market Reaction: Harrow reported full-year 2025 revenue of $272.3 million, a 36% increase year-over-year, and guided for 2026 revenue between $350 million and $365 million; however, the stock price fell sharply after missing EPS estimates, yet the long-term outlook remains positive.
- Strategic Adjustment Context: The 198,572 shares sold represent roughly 5% of Opaleye's total pre-sale position, indicating a meaningful trim that is likely a tactical adjustment for portfolio rebalancing or profit-locking rather than a strategic exit.
See More
LogiCare3PL Selected as Distribution Partner for Harrow's Ophthalmic Solutions
- Partnership Formation: LogiCare3PL was officially selected as a distribution partner for Harrow, Inc. effective February 1, 2026, providing both non-title and 3PL title distribution services to support Harrow's product distribution across the U.S., thereby enhancing Harrow's market access capabilities.
- Rapid Implementation Capability: LogiCare3PL successfully onboarded Harrow within just four weeks, meeting Harrow's implementation timeline and ensuring business continuity, which significantly improves Harrow's responsiveness in the competitive ophthalmic disease management market.
- High-Touch Service Model: LogiCare3PL was chosen for its high-touch service model and proven ability to execute quickly and efficiently, which not only met Harrow's need for rapid market readiness but also laid the groundwork for a long-term partnership between the two companies.
- Future Collaboration Outlook: Both organizations anticipate continued collaboration as Harrow expands its product offerings, with LogiCare3PL providing a full suite of 3PL services to further enhance Harrow's competitive position in the ophthalmic sector.
See More
LogiCare3PL Partners with Harrow for Ophthalmic Solutions Distribution
- Partnership Formation: LogiCare3PL officially became a distribution partner for Harrow, Inc. on February 1, 2026, providing both non-title and 3PL title distribution services, significantly enhancing Harrow's market access speed and cost-effectiveness in the U.S. market.
- Rapid Implementation Capability: LogiCare3PL successfully onboarded Harrow within just four weeks, meeting Harrow's implementation timeline and ensuring business continuity, showcasing LogiCare3PL's excellence in efficient execution and customer support.
- High-Touch Service Model: LogiCare3PL was selected for its high-touch service model and customer-centric flexibility, which not only met Harrow's need for rapid market readiness but also strengthened the long-term partnership between the two organizations.
- Future Collaboration Outlook: Both parties anticipate continued collaboration as Harrow expands its product offerings, with LogiCare3PL providing a full suite of 3PL services to further drive Harrow's growth in the ophthalmic disease management solutions sector.
See More
Harrow Prices $50 Million Private Offering of Senior Unsecured Notes
- Bond Offering Size: Harrow announced a private offering of $50 million in senior unsecured notes with an interest rate of 8.625% per annum, maturing in 2030, which will strengthen the company's capital structure and provide funding for future growth.
- Clear Use of Proceeds: The net proceeds from this bond issuance will be allocated for general corporate purposes, including new product launches, development activities, and strategic business opportunities, indicating the company's proactive approach to future expansion.
- Connection to Previous Issuance: The new notes will be issued under the same indenture as the previously issued $250 million of 2030 notes in September 2025, enhancing investor confidence in Harrow's debt profile.
- Issuance Timeline: The offering is expected to close on March 27, 2026, reflecting the company's active engagement in the capital markets and its focus on future financial flexibility.
See More
Harrow Plans to Issue $50M in Senior Unsecured Notes
- Bond Issuance Plan: Harrow announced its intention to offer $50 million in 8.625% senior unsecured notes due 2030, which will form a single series with the $250 million notes issued in September 2025, sharing identical terms except for issuance date and price.
- Clear Use of Proceeds: The net proceeds from this bond issuance will be allocated for general corporate purposes, including growth initiatives, product development, and potential strategic investments, indicating the company's proactive approach to future development.
- Positive Market Reaction: Following the announcement, Harrow's shares rose by 2.16%, reflecting investor confidence in the company's financing strategy and its future growth potential.
- Revenue Target Set: Harrow has set a revenue goal of $350 million to $365 million for 2026, anticipating performance growth driven by sales force expansion and pipeline advancements, further solidifying its dominant position in the U.S. ophthalmic market.
See More
Opaleye Management Inc. Indirectly Sells Harrow Shares Worth $7.8 Million
- Transaction Overview: Opaleye Management Inc. reported the indirect sale of 198,572 shares of Harrow common stock on March 3 and 4, 2026, totaling approximately $7.8 million, demonstrating its strategic maneuvering in a volatile market.
- Post-Transaction Holdings: Following the sale, Opaleye L.P. retains 3,622,000 shares and the managed account holds 59,428 shares, resulting in a combined indirect position of about 3.68 million shares, indicating that it remains a significant shareholder with nearly 10% ownership in Harrow.
- Market Reaction Analysis: While the nearly $8 million stock sale might suggest a lack of confidence, the context reveals that it occurred after Harrow's Q4 2025 earnings report, where the stock dropped sharply, making the sale appear more like opportunistic profit-taking rather than a fundamental outlook change.
- Investor Perspective: The shares sold represent roughly 5% of Opaleye's total pre-sale position, suggesting that the fund still has a strong belief in Harrow's long-term prospects, with this adjustment likely being tactical rather than a strategic retreat, reflecting confidence in Harrow's future growth potential.
See More
Opaleye Management Sells 198,572 Shares of Harrow Stock
- Sale Overview: Opaleye Management Inc. indirectly sold 198,572 shares of Harrow stock on March 3 and 4, 2026, for approximately $7.8 million, based on weighted average prices of $39.15 and $39.67, indicating opportunistic profit-taking following the company's earnings report.
- Holding Analysis: Despite the sale suggesting a potential lack of confidence in Harrow, Opaleye retains about 3.68 million shares, representing nearly 10% of Harrow's total shares, highlighting its continued role as a significant institutional backer.
- Financial Performance and Market Reaction: Harrow reported full-year 2025 revenue of $272.3 million, a 36% increase year-over-year, and guided for 2026 revenue between $350 million and $365 million; however, the stock price fell sharply after missing EPS estimates, yet the long-term outlook remains positive.
- Strategic Adjustment Context: The 198,572 shares sold represent roughly 5% of Opaleye's total pre-sale position, indicating a meaningful trim that is likely a tactical adjustment for portfolio rebalancing or profit-locking rather than a strategic exit.
See More
